Toshitsugu Sugimoto
Overview
Explore the profile of Toshitsugu Sugimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
313
Citations
5269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanaka S, Saito M, Hagino H, Mori S, Nakamura T, Ohta H, et al.
JBMR Plus
. 2022 Oct;
6(10):e10673.
PMID: 36248273
Associations between urinary pentosidine, one of the advanced glycation end products in collagen, and the risk of fracture in patients with severe osteoporosis are unknown. In this study, we investigated...
2.
Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, et al.
Osteoporos Int
. 2022 Oct;
34(1):189-199.
PMID: 36239756
Purpose: To determine whether the anti-fracture efficacy of sequential therapy with teriparatide, followed by alendronate is superior to that of monotherapy with alendronate, a prospective, randomized, open-label, blinded-endpoint trial was...
3.
Kuroda T, Shiraki M, Nakamura T, Suzuki H, Hiraishi K, Sugimoto T, et al.
Calcif Tissue Int
. 2021 Aug;
110(1):87-92.
PMID: 34427705
Although changes in serum sclerostin levels at 12 months after infusion of zoledronic acid have been reported, the changes in sclerostin levels at earlier time points are poorly understood. We...
4.
Shiraki M, Kuroda T, Takeuchi Y, Sugimoto T, Tanaka S, Suzuki H, et al.
Calcif Tissue Int
. 2021 Jul;
109(6):666-674.
PMID: 34247263
In a clinical trial involving Japanese patients with osteoporosis, post hoc analyses were performed to evaluate the incidence of acute phase reactions (APRs) after infusion of zoledronic acid (ZOL). The...
5.
Sugimoto T, Yoshimura T, Uzawa T
Osteoporos Sarcopenia
. 2021 Apr;
7(1):11-16.
PMID: 33869800
Objectives: To assess differences in efficacy of a 28.2-μg teriparatide formulation for twice-weekly use (2/W-TPTD) by patient characteristics. Methods: A analysis was performed using data from a multicenter, randomized, double-blind,...
6.
Takeno A, Kanazawa I, Tanaka K, Notsu M, Kanasaki K, Oono T, et al.
Diabetol Int
. 2021 Mar;
12(2):171-180.
PMID: 33786272
Diabetes mellitus is associated with bone fragility. Although osteoblast maturation is disturbed in patients with diabetes mellitus, the involvement of high glucose (HG) in different stages of osteoblast maturation is...
7.
Kanazawa I, Inaba M, Inoue D, Uenishi K, Saito M, Shiraki M, et al.
J Bone Miner Metab
. 2021 Mar;
39(4):721-722.
PMID: 33704574
No abstract available.
8.
Tanaka K, Morisato Y, Nakajima H, Kanasaki K, Sugimoto T, Kanazawa I
Intern Med
. 2020 Nov;
60(8):1191-1196.
PMID: 33229805
Objective Sarcopenia and osteoporosis often coexist in older adults. Sarcopenia is diagnosed using the skeletal muscle mass index (SMI), which is calculated as the appendicular skeletal muscle mass (ASM)/(present height),...
9.
Notsu M, Yamauchi M, Sugimoto T, Kanasaki K
Gynecol Endocrinol
. 2020 Sep;
36(12):1140-1143.
PMID: 32954874
Background: The epidemiology and natural history of autonomously functioning thyroid nodules (AFTNs) have not been elucidated. Here we report the pregnant Japanese woman with an AFTN. Case Presentation: The patient...
10.
Kanazawa I, Inaba M, Inoue D, Uenishi K, Saito M, Shiraki M, et al.
J Bone Miner Metab
. 2020 Sep;
38(6):746-758.
PMID: 32892240
Accumulating evidence has shown that patients with lifestyle diseases such as type 2 diabetes mellitus, chronic kidney disease, and chronic obstructive pulmonary disease are at increased risk of osteoporotic fracture....